Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kyntra Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.399 Thank you for standing by, and welcome to Kentra Bio's fourth quarter and full year 00:00:05.399 -- 00:00:10.446 2025 earnings conference call. At this time, all participants are in 00:00:10.446 -- 00:00:15.534 a listen-only mode. After the speaker presentation, there will be a question and answer 00:00:15.534 -- 00:00:20.582 session. To ask a question during the session, you will need to press star 1-1 on 00:00:20.582 -- 00:00:25.008 your telephone. To remove yourself from the queue, you may press star 1-1 again. 00:00:25.008 -- 00:00:30.871 I would now like to hand the call over to Gaia Shamus, with LifeSci Advisors. 00:00:30.871 -- 00:00:33.194 Please go ahead. 00:00:33.194 -- 00:00:35.017 Thank you, operator. 00:00:35.017 -- 00:00:39.964 Good afternoon, everyone. Thank you for joining today to discuss KintraBio's fourth quarter 00:00:39.964 -- 00:00:42.168 and full year 2025 00:00:42.168 -- 00:00:47.095 financial and business results. I'm Gaia Chamis from LifeSci Advisors. 00:00:47.095 -- 00:00:52.624 Joining me on today's call are Zane Wettig, Chief Executive Officer, David Ilchia, 00:00:52.624 -- 00:00:58.216 Chief Financial Officer, and Carol Gedum, Vice President of Product Development. 00:00:58.216 -- 00:01:01.960 Following the prepared remarks, we will open the call to your questions. 00:01:01.960 -- 00:01:06.164 I would like to remind you that remarks made on today's call include forward-looking 00:01:06.164 -- 00:01:11.809 statements about Kintra Bio. Such statements may include, but are not limited to, 00:01:11.809 -- 00:01:17.215 collaborations with AstraZeneca and Astellas, financial guidance, the initiation, 00:01:17.215 -- 00:01:22.360 enrollment, design, conduct, and results of clinical trials, regulatory 00:01:22...